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Background: Activation and signal transduction in the Nucleotide binding, leucine-rich repeat containing receptor
(NLR) family needs to be tightly regulated in order to control the inflammatory response to exogenous and
endogenous danger signals. Phosphorylation is a common cellular mechanism of regulation that has recently been
shown to be important in signalling in another family of cytoplasmic pattern recognition receptors, the RIG-I like
receptors. In addition, single nucleotide polymorphisms can alter receptor activity, potentially leading to dysfunction
and/or a predisposition to inflammatory barrier diseases.
Findings: We have computationally analysed the N-terminus of NOD1 and found seven theoretical phosphorylation
sites in, or immediately before, the NOD1 Caspase Activation Domain (CARD). Two of these, serine 7 and tyrosine 49 are
also found as rare polymorphisms in the African-American population and European-American populations respectively.
Mutating serine 7 to either an aspartic acid or an asparagine to mimic the potential impact of phosphorylation or
the polymorphism respectively did not affect the response of NOD1 to ligand-mediated NFκB signalling.
Conclusions: The NOD1 polymorphism S7N does not interfere with receptor function in response to ligand stimulation.
Keywords: NOD1, NOD2, SNP, Polymorphism, Phosphorylation, RIG-I, NLR, Pattern recognition receptor, Serine, Caspase
activation domain (CARD)Findings
Background
Tight regulation and control of innate immune pattern
recognition receptor (PRR) signalling pathways is essen-
tial to limit inappropriate receptor activation and excess
inflammation. PRR signalling can be altered as a result
of single nucleotide polymorphisms (SNPs). SNPs often
serve as risk factors, or predispositions, for specific dis-
eases. For example, in Nucleotide-binding Oligomerisa-
tion Domain (NOD) 2 the SNPs R702W, G908R, and
1007fsincC all inhibit receptor activation and predispose
to Crohn’s Disease [1,2]. In contrast the mutations
R334Q, R334W and L469F in the NOD region of NOD2
act as gain-of-function mutants and are associated with* Correspondence: tpm22@cam.ac.uk
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article, unless otherwise stated.Blau syndrome and Early Onset Sarcoidosis [3-6]. Simi-
larly, mutations in the NOD of the inflammasome form-
ing protein NLRP3 result in hyper- or auto-activation of
the receptor and lead to development of a spectrum of
inflammatory diseases collectively known as cryopyrin
associated periodic syndromes [7]. Polymorphisms in
NOD1 have been less extensively studied but the E266K
SNP has been linked to an increased risk of peptic ulcer-
ation in patients infected with Helicobacter Pylori [8].
Polymorphisms can affect protein function in unantici-
pated, and potentially unwelcome, ways. A more predict-
able and highly important mechanism of PRR regulation
is post-translational modification. For example, serine 8
in helix 1 of the first RIG-I (Retinoic inducible gene –I)
CARD and threonine 170 within helix 5 of the second
RIG-I CARD are phosphorylated by protein kinase C
alpha (PKCα) and PKCβ [9-12]. This restricts receptorntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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polyubiquitin and MAVS (mitochondrial antiviral signalling
protein). The activity of MDA5 (melanoma differentiation-
associated protein 5) is also influenced by phosphorylation.
In this instance receptor function is inhibited by phosphor-
ylation of serine 88 and serine 104; but stimulated when
these residues are dephosphorylated by phosphoprotein
phosphatase 1 α (PP1α) or PP1γ [13]. In the case of murine
NLRC4 phosphorylation of S533 by PKCδ serves to en-
hance receptor activation [14].
Previous studies and ongoing work in our own labora-
tory have investigated the functional role of residues in the
NOD1 CARD [15,16], but none have explicitly addressed
phosphorylation. Given the importance of CARD phos-
phorylation in the regulation of RIG-I and MDA-5 signal-
ling we hypothesised that serine 7 in human NOD1 could
be a possible candidate for the regulation of NOD1 signal-




The sequence of human NOD1 [Genbank: AAD28350.1]
was submitted to the NetPhos 2.0 server [17] for the
identification of potential serine, threonine and tyrosine
phosphorylation sites. Solvent accessibility of residues in
the monomeric [PDB: 2dbd] and dimeric [PDB: 2nz7]
[18] forms of the NOD1 CARD was determined using
ASAview [19]. Mammalian NOD1 orthologues were
recovered from the NCBI non-redundant protein data-
base using blastp (protein-protein BLAST) with hu-
man NOD1 [Genbank: AAD28350.1] as a search term
using the standard parameters. Sequences were collated in
FASTA format, aligned using MUSCLE [20] and incom-
plete or duplicate sequences manually removed. Thirty-six
orthologues remained in the final alignment and the level
of identity with human NOD1 residues 1-120 containing
the CARD is shown in parentheses (all sequences were re-
covered from the NCBI REFSEQ database): Ailuropoda
melanoleuca (84%) [REFSEQ: XP_002919315.1]; Bos taurus
(83%) [REFSEQ: XP_598513.3]; Callithrix jacchus (95%)
[REFSEQ: XP_002751479.1]; Canis lupus familiaris (86%)
[REFSEQ: XP_539499.3]; Ceratotherium simum simum
(88%) [REFSEQ: XP_004418924.1]; Condylura cristata
(85%) [REFSEQ: XP_004677197.1]; Cricetulus griseus
(83%) [REFSEQ: XP_003507840.1]; Dasypus novemcinctus
(88%) [REFSEQ: XP_004453256.1]; Echinps telfairi (71%)
[REFSEQ: XP_004702914.1]; Equus caballus (88%) [REF
SEQ: XP_001499616.1]; Felis catus (88%) [REFSEQ: XP_
003982953.1]; Heterocephalus_glaber (83%) [REFSEQ: EHB
11938.1]; Homo Sapiens [REFSEQ: NP_006083.1]; Jaculus
jaculus (78%) [REFSEQXP_004652693.1]; Loxodonta_afri-
cana (83%) [REFSEQ: XP_003407068.1]; Macaca fascicu-
laris (98%) [REFSEQ: EHH52238.1]; Macaca mulatta (98%)[REFSEQ: EHH17407.1]; Mus musculus (79%) [REFSEQ:
NP_766317.1]; Mustela putorius furo (84%) [REFSEQ:
XP_004762622.1]; Nomascus leucogenys (99%) [REFSEQ:
XP_003270528.1]; Octodon degus (86%) [REFSEQ: XP_
004626575.1]; Odobenus rosmarus divergens (89%) [REFS
EQ: XP_004414009.1]; Orcinus orca (82%) [REFSEQ:
XP_004269993.1]; Ornithorhynchus anatinus (69%) [REF
SEQ: XP_001512159.1]; Oryctolagus cuniculus (83%)
[REFSEQ: XP_002713781.1]; Otolemur garnettii (84%)
[REFSEQ: XP_003788597.1]; Ovis aries (80%) [REFSEQ:
XP_004007979.1]; Pan troglodytes (100%) [REFSEQ:
XP_001165528.1]; Pan paniscus (100%) [REFSEQ: XP_0
03833425.1]; Papio Anubis (98%) [REFSEQ: XP_003896
196.1]; Pongo abelii (98%) [REFSEQ: XP_002818130.1];
Rattus norvegicus (78%) [REFSEQ: NP_001102706.1];
Saimiri boliviensis boliviensis (93%) [REFSEQ: XP_003935
228.1]; Sorex araneus (67%) [REFSEQ: XP_004604307.1];
Sus scrofa (83%) [REFSEQ: BAG12313.1]; Trichechus man-
atus latirostris (82%) [REFSEQ: XP_004377558.1].
Consensus sequence images were generated using
WebLogo v3.3 [21]. Molecular structure images were
created using The PyMOL Molecular Graphics System,
Version 1.5.0.5 Schrödinger, LLC. SNP frequencies were
retrieved from the “Exome Variant Server” (http://evs.gs.
washington.edu/EVS/).
Plasmids
pUNO-NOD1 encodes full-length untagged human NOD1
and was a kind gift from Dr Peter Murray. Point mutants
S7N, S7D and E56K were generated in the pUNO-NOD1
vector by site-directed mutagenesis. The plasmids pLuc
and phrG (Promega) are components of the dual-luciferase
assay and encode Firefly and Renilla luciferase respectively.
NFκB-luciferase reporter assays
HEK293 cells were maintained in DMEM (Sigma) supple-
mented with 10% FCS, 100 μg/ml Penicillin/Streptomycin
and 2 mM L-glutamine at 37°C and 5% CO2. Assays were
performed in 96-well plates and 0.1 ng/well of the appro-
priate NOD1 plasmid was transfected using jetPEI (Poly-
plus Transfection) along with 1 ng/well of pLuc and phrG.
Stimulation with up to 1000 ng/ml of ie-DAP (Invivogen),
or 100 ng/ml of the control ligand iE-Lys (Invivogen) was
performed simultaneously with transfection. 24 h later
cells were lysed with 1 × passive lysis buffer (Promega)
and luminescence measured with a FLUORstar Lumin-
ometer (BMG Labtech). Statistical analysis was performed
on the data using an unpaired t-test with Welch’s correc-
tion for unequal variances. Protein expression was
checked 24 h after transfection of HEK293 cells with 3 μg/
DNA per well in a 6 well plate in the absence of stimula-
tion. Proteins were visualised by western blot using the
NOD1 monoclonal antibody 2A10 [22] and anti-GAPDH
(Abcam: ab9485).
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Results and discussion
Potential serine, threonine and tyrosine phosphorylation
sites in and immediately adjacent to the CARD of the
NLR family member NOD1 were identified using the pre-
diction software NETPhos 2.0. Within the first 120 resi-
dues of human NOD1 (CARD structure 19-110) there
were four predicted serine phosphorylation sites (residues
7, 25, 51, and 77); one predicted threonine phospho-
rylation site (residue 37); and two predicted tyrosine
phosphorylation sites (residues 49 and 97) (Figure 1A).
Analysis of the Exome Variant Server indicated that two of
these residues are present as low frequency polymor-
phisms. Serine 7 is replaced with an asparagine in appro-
ximately 1 in 2200 of the African-American population;
whilst tyrosine 49 is mutated to a cysteine in approximately
1 in 8500 of the European-American population.
We mapped the position of the potential phosphoryl-
ation sites onto the structure of the NOD1 CARD. Serine
7 is immediately prior to the structured CARD; serine 25 is
within helix 1; threonine 37 is in the helix 1 – helix 2 loop;
tyrosine 49 and serine 51 are in the helix 2 – helix 3 loop;
serine 77 is in helix 4; and tyrosine 99 in the helix 5 – helix
6 loop (Figure 1B). The relative surface accessibility of10 20        30
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Figure 1 Location of potential phosphorylation sites in the NOD1 CA
the first 120 residues of NOD1 were identified using NETPhos 2.0. (A) Locat
first 120 residues of NOD1. Black boxes denote the location of helices in th
representations on the tertiary structure of the NOD1 CARD [PDB: 2dbd]. Th
vertical axis. Colouring in (A) and (B) is as follows: green – serine, pink – ththese residues was determined using ASAview [19] from
the NMR structure of the NOD1 CARD [PDB ID: 2dbd].
Serine 7 is not included in the structure so no information
could be obtained for this residue. Its position near the
start of the protein, prior to the first structured domain,
makes it plausible that it is surface exposed; though the
possibility remains that it may pack against the CARD
helices in a manner that would inhibit kinase access.
The order of relative surface accessibility of the remaining
sites runs as follows: S77 > S25 > S51 > Y49 > Y97 > T37.
As crystal structures of the NOD1 CARD show formation
of a homodimer we also checked the relative surface ac-
cessibility of these residues in the dimeric form [PDB
ID:2nz7]. The pattern of accessibility was broadly similar
with the overall order S77 > S25 > S51 > Y49 > T37 > Y97.
T37 and Y97 were consistently the two least accessible po-
tential targets for phosphorylation in the whole CARD
structure, making it highly unlikely that these residues
undergo post-translational modification.
Given the importance of serine phosphorylation in the
regulation of RIG-I signalling and the potential for poly-
morphisms to disrupt receptor activity we mutated serine
7 to an asparagine to mimic the polymorphism; and to an
aspartic acid to mimic phosphorylation. The ability of
these mutants to activate NFκB signalling was then tested
in HEK293 cells using a dual-luciferase NFκB reporter
assay system. Both of the serine 7 mutants signalled in
an identical manner to wild-type NOD1 in response to40        50        60
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RD. Potential serine, threonine and tyrosine phosphorylation sites in
ion of potential phosphorylation sites in the primary sequence of the
e CARD. (B) Potential phosphorylation residues are shown as ball
e left and right images are related by a 180° rotation around the
reonine, yellow - tyrosine.
Table 1 Conservation of potential phosphorylation sites
across 36 mammalian species
Residue Residue conservation
Serine 7 21 serine, 5 glycine, 4 histidine, 4 arginine,
1 cysteine, 1 isoleucine
Serine 25 12 isoleucine, 10 serine, 9 valine, 4 threonine,
1 alanine
Threonine 37 34 threonine, 2 isoleucine
Tyrosine 49 36 tyrosine
Serine 51 19 alanine, 6 threonine, 5 serine, 3 glutamic
acid, 1 isoleucine, 1 asparagine, 1 valine
Serine 77 36 serine
Tyrosine 97 36 tyrosine
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nopimelic acid (iE-DAP). In contrast, the mutation E56K
removed the ability of NOD1 to respond to ligand stimu-
lation consistent with previous studies (p < 0.0005) [16]
(Figure 2A). Western blot analysis confirmed that each
construct expressed at a level comparable to wild-type
protein (Figure 2B).
To reinforce the lack of impact on NOD1 function fol-
lowing mutation of serine 7 we compared the sequence
conservation of this residue in NOD1 across 36 different
mammalian species. Although serine was the most com-
mon residue in this position (21/36), numerous other
































































Figure 2 Mutation of serine 7 does not affect NOD1 function.
(A) NFκB promoter-luciferase reporter assay of NOD1 pUNO wild
type (WT), S7D, S7N and E56K in HEK293 cells. 0.1 ng/well DNA was
stimulated with increasing doses of the ligand, iE-DAP, or 100 ng/ml
of the inactive control ligand iE-Lys (C100). Cells were incubated for
24 hours before lysis. Results show the average of three independent
experiments. *** = p < 0.0005. Error bars indicate SEM. (B) Immunoblots
detecting expression of NOD1 pUNO WT, S7D, S7N, E56K and vector
(pUNO) in HEK293 cells. Cells were transfected with 1.5 μg DNA and
incubated for 24 hours in the absence of ligand and lysed and probed
with the specified antibodies. Results are representative of three
independent experiments.arginine (4/36), histidine (4/36), cysteine (1/36) and iso-
leucine (1/36) (Table 1 and Figure 3). The lack of exten-
sive conservation in this position is consistent with a
lack of role for phosphorylation of serine 7 in NOD1
function; and also with the lack of impact on receptor
signalling of the S7N polymorphism. We also compared
the cross-species conservation of the other putative
phosphorylation sites (Table 1). Serine 25 and serine 51
were poorly conserved making it unlikely that they are
important sites of phosphorylation. Threonine 37 was
conserved in 34/36 species, whilst serine 77, tyrosine 49
and tyrosine 97 were all completely conserved. Combin-
ing the level of conservation with the relative surface ac-
cessibility suggests that serine 77 is a prime candidate
for phosphorylation; that threonine 37 and tyrosine 97
play important structural roles; and that tyrosine 49 may
be a potential phosphorylation target.
This work has identified residues that may be poten-
tially phosphorylated in the NOD1 CARD and which
consequently have the potential to modulate receptor
activity in a manner analogous to that seen with RIG-IFigure 3 Serine 7 shows limited conservation in mammalian
NOD1. A sequence logo representation of the first 10 amino acids
of NOD1 in which letter height reflects the likelihood of finding a
particular residue in that position. The location of serine 7 is marked
with a purple arrow.
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residues, serine 7, to either an aspartic acid to mimic
phosphorylation, or to asparagine to reflect the natural
polymorphism S7N does not affect receptor function.
We can therefore conclude that the SNP S7N has no im-
pact on NOD1 activation and signalling and that serine
7 is not involved in regulation of NOD1 signalling.
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